Answers are grounded in this paper and cite their sources.
Introduction The present study aimed at developing and optimizing a bio-inspired, deformable nanovesicular system (Spanlastics, SPLs), loaded with Vardenafil (VDF), as localized therapeutic approach to attenuate ischemic tissue damage in severe microangiopathy. Method Using a Box–Behnken design (23), the effects of three independent variables—Span 60 amount, Tween 80 amount, and sonication time—were investigated. Results and Discussion The optimized formulation exhibited a mean particle size of 57 nm, a Polydispersity Index (PDI) of 0.3, and a Zeta Potential of -37 mV, achieving an entrapment efficiency (EE%) of 89.7% and, exhibiting a cumulative release of 37% after 8 h. For ease of topical application, the optimized SPLs were then incorporated into HPMC hydrogel. The therapeutic efficacy of the optimized VDF-SPLs gel was validated in an in-vivo peripheral ischemic model by monitoring tissue microcirculation and vasodilatory biomarkers (cGMP and NO). EE% decreased with increasing Span 60 concentration, whereas vesicle size increased. Interfacial modification with elevated Tween 80 concentrations effectively sustained drug release rates. TEM confirmed highly uniform, spherical nanovesicles for the optimized formulation. The optimized VDF-SPLs hydrogel showed a profound 1.69-fold enhancement in skin permeation flux compared to the pure drug gel control. In-vivo pharmacodynamic evaluation confirmed robust reversal of local vascular constriction and microvascular salvage, driven by a significant upregulation of local and serum levels. The localized delivery of vardenafil via optimized bio-inspired elastic nanovesicles provides an effective, non-invasive therapeutic paradigm to upregulate the pathway and attenuate tissue ischemia in severe peripheral microangiopathies.
No takes yet. Share an insight, caveat, or question.
Gomaa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: